Stock AnalizSolventum Corp SOLV
Medical/Dental Instruments · IPO 2024 · data as of November 13, 2026
Solventum Corp (SOLV) is a healthcare company listed in the US with a market value of about $15.1B. In the twelve months to September 30, 2026 it had revenue of $8.2B and net income of $156M, a net margin of 1.9%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a P/E of 101.2, a 5-year average ROIC of 12%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 32% below the current price.
Score: 1.2 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year average ROIC above 12%
- ROE above 15%
- Interest covered more than 5 times
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $8.2B | $8.3B | $8.3B | $8.2B | $8.1B |
| Net income | $156M | $1.6B | $479M | $1.3B | $1.3B |
| Free cash flow | $0 | -$10M | $805M | $1.6B | $1.4B |
| EPS (diluted) | $0.88 | $8.88 | $2.76 | $7.79 | $7.78 |
| Net margin | 1.9% | 18.7% | 5.8% | 16.4% | 16.5% |
| ROIC | — | 19.2% | 7.3% | 11.6% | 11.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $98.38, 10% above the current price; targets range from $75.00 to $115.00; the consensus rating is “Buy”; expected EPS is $7.24 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Solventum’s P/E ratio?
About 101.2, based on the last twelve months of diluted earnings per share (forward P/E about 12.3).
Is Solventum stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 32% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Solventum pay a dividend?
Not currently.
Is Solventum a good stock to buy?
We do not give buy or sell advice. Solventum scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.